PRAX$280.512.38%6.52
Praxis Precision Medicines Inc (PRAX)
Date: 2026-11-03 16:00O: 277.76H: 286.04L: 276.00C: 280.51Vol: 220.5k
Praxis Precision Medicines Inc stock is traded at $280.51, with a volume of 220,549. It is up +2.38% in the last 24 hours and down -5.08% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Previous Close:
$273.99
Open:
$277.76
24h Volume:
220,549
Relative Volume:
0.60
Market Cap:
$7.83B
Revenue:
$7.46M
Net Income/Loss:
-$326.53M
P/E Ratio:
-
EPS:
-$13.38
Net Cash Flow:
-$282.53M
1W Performance:
-1.74%
1M Performance:
-5.08%
6M Performance:
-16.91%
1Y Performance:
+63.32%
1-Day Range:
$0.00$0.00
1-Week Range:
$272.72$294.95
52-Week Range:
$154.45$392.70
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines IncSector
HealthcareIndustry
BiotechnologyPhone
617-300-8460Address
99 HIGH STREET, 30TH FLOOR, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
- DeSimone JillJun 24 '26Director
- Transaction
- Sale
- Cost
- $311.32
- #Shares
- 11,600
- Value ($)
- 3,611,335
- #Shares Total
- 2,337
- DeSimone JillJun 24 '26Director
- Transaction
- Proposed Sale
- Cost
- $311.32
- #Shares
- 11,600
- Value ($)
- 3,611,336
- #Shares Total
- 0
- DeSimone JillJun 24 '26Director
- Transaction
- Option Exercise
- Cost
- $71.20
- #Shares
- 11,600
- Value ($)
- 825,954
- #Shares Total
- 13,937
- Nemiroff AlexNov 20 '25Officer
- Transaction
- Proposed Sale
- Cost
- $193.09
- #Shares
- 25,130
- Value ($)
- 4,852,249
- #Shares Total
- 0
- Mastrocola LaurenNov 20 '25Principal Accounting Officer
- Transaction
- Option Exercise
- Cost
- $61.12
- #Shares
- 13,600
- Value ($)
- 831,257
- #Shares Total
- 24,042
- Mastrocola LaurenNov 20 '25Principal Accounting Officer
- Transaction
- Sale
- Cost
- $192.08
- #Shares
- 13,600
- Value ($)
- 2,612,244
- #Shares Total
- 10,442
- Nemiroff AlexNov 20 '25General Counsel and Secretary
- Transaction
- Sale
- Cost
- $193.09
- #Shares
- 25,130
- Value ($)
- 4,852,256
- #Shares Total
- 20,832
- Mastrocola LaurenNov 20 '25Officer
- Transaction
- Proposed Sale
- Cost
- $192.08
- #Shares
- 13,600
- Value ($)
- 2,612,239
- #Shares Total
- 0
- Nemiroff AlexNov 20 '25General Counsel and Secretary
- Transaction
- Option Exercise
- Cost
- $73.76
- #Shares
- 25,130
- Value ($)
- 1,853,531
- #Shares Total
- 45,962
- Director
- Transaction
- Option Exercise
- Cost
- $39.51
- #Shares
- 12,251
- Value ($)
- 483,991
- #Shares Total
- 17,251
